<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JIC</journal-id>
<journal-id journal-id-type="hwp">spjic</journal-id>
<journal-id journal-id-type="nlm-ta">J Intensive Care Med</journal-id>
<journal-title>Journal of Intensive Care Medicine</journal-title>
<issn pub-type="ppub">0885-0666</issn>
<issn pub-type="epub">1525-1489</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0885066611402156</article-id>
<article-id pub-id-type="publisher-id">10.1177_0885066611402156</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Intravenous Ibandronate Acutely Reduces Bone Hyperresorption in Chronic Critical Illness</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Via</surname>
<given-names>Michael A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0885066611402156">1</xref>
<xref ref-type="corresp" rid="corresp1-0885066611402156"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Potenza</surname>
<given-names>Matthew V.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0885066611402156">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hollander</surname>
<given-names>Jason</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0885066611402156">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Xuan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0885066611402156">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Yuanzhen</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff4-0885066611402156">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Jianhua</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff4-0885066611402156">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Li</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff5-0885066611402156">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zaidi</surname>
<given-names>Mone</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0885066611402156">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mechanick</surname>
<given-names>Jeffrey I.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-0885066611402156">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0885066611402156">
<label>1</label>Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA</aff>
<aff id="aff2-0885066611402156">
<label>2</label>Diabetes &amp; Endocrinology, West Nyack, NY, USA</aff>
<aff id="aff3-0885066611402156">
<label>3</label>Princeton Endocrinology, Princeton, New Jersey, Princeton, NJ, USA</aff>
<aff id="aff4-0885066611402156">
<label>4</label>The Mount Sinai Bone Program, Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, USA</aff>
<aff id="aff5-0885066611402156">
<label>5</label>Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, USA</aff>
<author-notes>
<corresp id="corresp1-0885066611402156">Michael A. Via, MD, Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, 55 East 34th St., New York, NY 10016, USA. Email: <email>mvia@chpnet.org</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>5</issue>
<fpage>312</fpage>
<lpage>318</lpage>
<history>
<date date-type="received">
<day>8</day>
<month>7</month>
<year>2010</year>
</date>
<date date-type="rev-recd">
<day>31</day>
<month>8</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>9</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Objective:</title><p>Patients who remain critically ill for prolonged periods and require tracheotomy, defined as chronic critical illness (CCI), display elevated levels of bone resorption. The measurement of bone turnover markers reveals that osteoclastic bone resorption is not only enhanced but also uncoupled from osteoblastic bone formation. We examine the effect of ibandronate on bone turnover in patients with CCI.</p></sec>
<sec><title>Methods:</title><p>This study is a prospective, double-blind, placebo-controlled trial, in which 20 postmenopausal female participants with CCI were followed for an 11-day period after the administration of a single intravenous dose of ibandronate (3 mg). All participants were treated with ergocalciferol (2000 IU daily), calcium carbonate (1250 mg daily), and calcitriol (0.25 μg daily).</p></sec>
<sec><title>Results:</title><p>The ibandronate group showed a 34% decrease in serum C-telopeptide (CTX) levels (a marker of osteoclastic activity) on day 6, while the placebo group showed a 13% increase (<italic>P</italic> = .01). By day 11, CTX levels in ibandronate group were not significantly different than baseline or from the placebo group. Osteocalcin (OCN) levels (a marker of osteoblast activity) increased by 78% compared to baseline in the ibandronate group (<italic>P</italic> = .01) and by 42% in the placebo group (<italic>P</italic> = .05). There were no significant differences in OCN between the 2 groups throughout the study. Parathyroid hormone levels remained constant throughout the study. No adverse events were observed.</p></sec>
<sec><title>Conclusion:</title><p>A single dose of intravenous ibandronate causes a significant but transient reduction in osteoclast activity in patients with CCI, which persists over a 6-day period.</p></sec>
</abstract>
<kwd-group>
<kwd>chronic critical illness</kwd>
<kwd>ibandronate</kwd>
<kwd>bone resorption</kwd>
<kwd>osteoporosis</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>September/October 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-0885066611402156">
<title>Introduction</title>
<p>Hyperresorption of the skeleton is an underrecognized and typically untreated complication in critically ill patients during both the acute and chronic stages.<sup><xref ref-type="bibr" rid="bibr1-0885066611402156">1</xref>,<xref ref-type="bibr" rid="bibr2-0885066611402156">2</xref></sup> Of critically ill patients, 92% display elevated N-telopeptide (NTX) levels.<sup><xref ref-type="bibr" rid="bibr3-0885066611402156">3</xref><xref ref-type="bibr" rid="bibr4-0885066611402156"/>–<xref ref-type="bibr" rid="bibr5-0885066611402156">5</xref></sup> Urinary pyridinoline and deoxypyridinoline levels can rise by 6- to 12-fold. The clinical impact of such hyperresorption is greater in patients who have survived acute critical illness but remain mechanically ventilated.<sup><xref ref-type="bibr" rid="bibr1-0885066611402156">1</xref></sup> We define this group as having chronic critical illness (CCI). These patients are severely debilitated and catabolic; the loss of lean body mass and hyperresorption can together have devastating effects on their already compromised medical status.<sup><xref ref-type="bibr" rid="bibr2-0885066611402156">2</xref></sup>
</p>
<p>Several factors contribute to the high prevalence of hyperresorption in CCI. These include excessive cytokine-mediated osteoclast formation,<sup><xref ref-type="bibr" rid="bibr6-0885066611402156">6</xref></sup> a high rate of vitamin D insufficiency (91%-97%),<sup><xref ref-type="bibr" rid="bibr3-0885066611402156">3</xref>,<xref ref-type="bibr" rid="bibr7-0885066611402156">7</xref></sup> prolonged immobilization,<sup><xref ref-type="bibr" rid="bibr8-0885066611402156">8</xref>,<xref ref-type="bibr" rid="bibr9-0885066611402156">9</xref></sup> commonly used medications including glucocorticoids or heparin,<sup><xref ref-type="bibr" rid="bibr1-0885066611402156">1</xref></sup> and anterior pituitary gland dysfunction leading to growth hormone deficiency, decreased gonadal function, and elevated circulating cortisol levels.<sup><xref ref-type="bibr" rid="bibr10-0885066611402156">10</xref></sup>
</p>
<p>Through its effect on the microarchitecture of bone, hyperresorption is known to induce an increased risk of fracture in addition to the observed decrease in bone mineral density.<sup><xref ref-type="bibr" rid="bibr1-0885066611402156">1</xref></sup> Thus, treatments that target the osteoclast potentially attenuate hyperresorption and may impact its skeletal and nonskeletal complications in patients with CCI. Indeed, pamidronate, a bisphosphonate with established efficacy on the hyperresorption of malignancy,<sup><xref ref-type="bibr" rid="bibr11-0885066611402156">11</xref></sup> was found to be efficacious in patients with CCI. In our, albeit small, retrospective study, an impressive 70% reduction in NTX levels was noted after a single dose of pamidronate, which lasted for 18 days.<sup><xref ref-type="bibr" rid="bibr12-0885066611402156">12</xref></sup> In contrast, both low-dose calcitriol and cholecalciferol were unable to attenuate elevations in osteoclast activity in patients with CCI.<sup><xref ref-type="bibr" rid="bibr5-0885066611402156">5</xref>,<xref ref-type="bibr" rid="bibr12-0885066611402156">12</xref></sup>
</p>
<p>Here, we report the efficacy and safety of a single intravenous dose of ibandronate, a second-generation nitrogen-containing bisphosphonate, as an agent to inhibit bone hyperresorption in patients with CCI. This is the first prospectively designed, double-blind, placebo-controlled therapeutic trial to test the efficacy of any bisphosphonate in this patient population. Compared with other intravenous bisphosphonates, ibandronate has a superior safety profile, including a reduced rate of renal dysfunction.<sup><xref ref-type="bibr" rid="bibr13-0885066611402156">13</xref></sup>
</p>
<p>To control for gender differences and for the confounding effects of gonadal hormones on bone metabolism, study enrollment was limited to postmenopausal women with CCI.</p>
</sec>
<sec id="section2-0885066611402156" sec-type="methods">
<title>Methods</title>
<sec id="section3-0885066611402156">
<title>Study Patients</title>
<p>The study was approved by the Mount Sinai Medical Center Institutional Review Board. All postmenopausal female patients admitted to the respiratory care unit (RCU) during the approved study period were considered for enrollment. The RCU accepts adult patients from the medical intensive care unit (MICU), surgical intensive care unit (SICU), coronary care unit (CCU), cardiothoracic surgical intensive care unit (CSICU), and neurosurgical intensive care unit (NICU) that have survived acute critical illness, but require continued critical care and mechanical ventilation. Participants included in the study met criteria for CCI<sup><xref ref-type="bibr" rid="bibr2-0885066611402156">2</xref></sup>: they had survived at least 5 days of critical care and had a tracheostomy performed for anticipated prolonged dependence on mechanical ventilation.</p>
<p>Patients were excluded from the study if they had one or more of the following: an established condition currently requiring bisphosphonate therapy, such as metastatic disease or hypercalcemia; previous therapy with bisphosphonates, calcitonin, raloxifene, or teriparatide in the preceding 6 months; a creatinine clearance (CrCl) ≤30 mL/min estimated by the Crockoft-Gault equation; febrile to temperatures above 38°C; or an expected hospital discharge within 14 days.</p>
</sec>
<sec id="section4-0885066611402156">
<title>Study Design</title>
<p>The study was a 14-day-long, randomized, double-blind, placebo-controlled therapeutic trial. Participants who met inclusion criteria and gave informed written consent were supplemented with ergocalciferol 2000 IU, calcium carbonate 1250 mg and calcitriol 0.25 µg (all enterally per os or via feeding tube or, if needed, parenterally). After 3 days of supplementation, participants were randomized to receive either ibandronate (Roche Pharmaceuticals, Basel, Switzerland), 3 mg intravenous injection over 5 minutes, or placebo. Participants were followed for 14 days. Markers of bone metabolism, including C-telopeptide (CTX) and osteocalcin (OCN), as well as intact parathyroid hormone (PTH), were measured at baseline and 3, 6, and 11 days following treatment. The primary endpoint was a change in the CTX level, reflecting osteoclastic activity and the degree of bone resorption.</p>
</sec>
<sec id="section5-0885066611402156">
<title>Safety Monitoring</title>
<p>Participants were monitored for adverse events, including fever, atrial fibrillation, diminished renal function, osteonecrosis of the jaw, and any other untoward medical event that occurred during or within 3 months after the trial.</p>
</sec>
<sec id="section6-0885066611402156">
<title>Biochemical Studies</title>
<p>Early morning fasting blood samples were collected, frozen in liquid nitrogen, and stored at −80°C. Serum CTX, OCN, and intact PTH were measured using the Serum Crosslaps enzyme-linked immunosorbent assay (Immunodiagnostic Systems, Fountain Hills, Arizona). Serum samples were sent to The Mount Sinai Hospital Clinical Laboratory for measurement of calcium, phosphorus, creatinine, 25-hydroxyvitamin D, 1,25-hydroxyvitamin D, and albumin levels. Calcium was corrected for albumin levels using the following equation: total calcium corrected = total calcium measured + ([4.0 − serum albumin] × 0.8).</p>
</sec>
<sec id="section7-0885066611402156">
<title>Statistical Analysis</title>
<p>The study was powered at 85% to detect differences in relative reduction in CTX by at least 50% between the ibandronate-treated group and placebo group using 2-sided testing with α = .05. Biochemical data are presented as means ± standard deviations. C-telopeptide and OCN levels are expressed as percentage change from baseline. Between-group comparisons were done using ANOVA and Student <italic>t</italic> test, where appropriate. Data were analyzed using a per protocol approach, since all enrolled patients received either treatment or placebo as a one-time intervention.</p>
</sec>
</sec>
<sec id="section8-0885066611402156">
<title>Results</title>
<p>Of 45 consecutive RCU patients screened, 20 (44%) met inclusion criteria and were randomly assigned to a study group. All 20 enrolled patients completed the 14-day trial (<xref ref-type="fig" rid="fig1-0885066611402156">Figure 1</xref>
). There were no significant differences in baseline characteristics between the study groups (<xref ref-type="table" rid="table1-0885066611402156">Table 1</xref>
). Overall, 90% of enrolled participants were either vitamin D insufficient (15–30 ng/mL; 50%) or vitamin D deficient (&lt;15 ng/mL; 40%). All patients had albumin levels less than 3 g/dL. Calcium (corrected) and phosphorus levels were in the normal range.</p>
<fig id="fig1-0885066611402156" position="float">
<label>Figure 1.</label>
<caption>
<p>Study subject enrollment and group assignment. Creatinine clearance, CrCl.</p>
</caption>
<graphic xlink:href="10.1177_0885066611402156-fig1.tif"/>
</fig>
<table-wrap id="table1-0885066611402156" position="float">
<label>Table 1.</label>
<caption>
<p>Baseline study patient demographics</p>
</caption>
<graphic alternate-form-of="table1-0885066611402156" xlink:href="10.1177_0885066611402156-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Ibandronate (n = 10)</th>
<th>Placebo (n = 10)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>62 ± 13</td>
<td>66 ± 14</td>
<td>.88</td>
</tr>
<tr>
<td>25-OH Vitamin D</td>
<td>
</td>
<td>
</td>
<td>.29</td>
</tr>
<tr>
<td> &lt;15 ng/mL</td>
<td align="center">3</td>
<td align="center">5</td>
<td>
</td>
</tr>
<tr>
<td> 15–30 ng/mL</td>
<td align="center">5</td>
<td align="center">5</td>
<td>
</td>
</tr>
<tr>
<td>Corticosteroid use</td>
<td align="center">4</td>
<td align="center">8</td>
<td>.17</td>
</tr>
<tr>
<td>ICU prior to RCU</td>
<td>
</td>
<td>
</td>
<td>.41</td>
</tr>
<tr>
<td> MICU</td>
<td align="center">5</td>
<td align="center">5</td>
<td>
</td>
</tr>
<tr>
<td> SICU</td>
<td align="center">1</td>
<td align="center">3</td>
<td>
</td>
</tr>
<tr>
<td> CCU</td>
<td align="center">0</td>
<td align="center">1</td>
<td>
</td>
</tr>
<tr>
<td> CSICU</td>
<td align="center">1</td>
<td align="center">0</td>
<td>
</td>
</tr>
<tr>
<td> NICU</td>
<td align="center">3</td>
<td align="center">1</td>
<td>
</td>
</tr>
<tr>
<td>Reason for ventilator dependence</td>
<td>
</td>
<td>
</td>
<td>.14</td>
</tr>
<tr>
<td> Acute lung disease</td>
<td align="center">3</td>
<td align="center">6</td>
<td>
</td>
</tr>
<tr>
<td> Chronic lung disease</td>
<td align="center">3</td>
<td align="center">0</td>
<td>
</td>
</tr>
<tr>
<td> Postsurgical</td>
<td align="center">4</td>
<td align="center">4</td>
<td>
</td>
</tr>
<tr>
<td>Duration of admission (days)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> ICU</td>
<td>17 ± 7</td>
<td>19 ± 10</td>
<td>.56</td>
</tr>
<tr>
<td> Step down unit</td>
<td>36 ± 14</td>
<td>35 ± 12</td>
<td>.13</td>
</tr>
<tr>
<td> Total hospitalization</td>
<td>57 ± 17</td>
<td>57 ± 18</td>
<td>.22</td>
</tr>
<tr>
<td>Patient outcome</td>
<td>
</td>
<td>
</td>
<td>.87</td>
</tr>
<tr>
<td> Weaned from ventilator</td>
<td align="center">7</td>
<td align="center">8</td>
<td>
</td>
</tr>
<tr>
<td> Remained ventilator dependant</td>
<td align="center">3</td>
<td align="center">2</td>
<td>
</td>
</tr>
<tr>
<td> Discharged from hospital</td>
<td align="center">10</td>
<td align="center">10</td>
<td>
</td>
</tr>
<tr>
<td> Death</td>
<td align="center">0</td>
<td align="center">0</td>
<td>
</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.5 ± 0.2</td>
<td>0.6 ± 0.2</td>
<td>.10</td>
</tr>
<tr>
<td>25-OH Vitamin D, ng/mL</td>
<td>21 ± 16</td>
<td>14 ± 8</td>
<td>.23</td>
</tr>
<tr>
<td>1,25-OH Vitamin D, pg/mL</td>
<td>39 ± 42</td>
<td>17 ± 13</td>
<td>.25</td>
</tr>
<tr>
<td>Corrected calcium, mg/dL</td>
<td>10.2 ± 0.5</td>
<td>9.9 ± 0.5</td>
<td>.79</td>
</tr>
<tr>
<td>Albumin, g/dL</td>
<td>2.6 ± 0.4</td>
<td>2.5 ± 0.3</td>
<td>.78</td>
</tr>
<tr>
<td>Phosphorus, mg/dL</td>
<td>3.9 ± 0.8</td>
<td>3.6 ± 0.8</td>
<td>.46</td>
</tr>
<tr>
<td>PTH, pg/mL</td>
<td>51 ± 43</td>
<td>76 ± 60</td>
<td>.13</td>
</tr>
<tr>
<td>Urine calcium, mg/24 h</td>
<td>124 ± 87</td>
<td>93 ± 88</td>
<td>.80</td>
</tr>
<tr>
<td>C-telopeptide, ng/mL</td>
<td>1.5 ± 0.3</td>
<td>1.1 ± 0.1</td>
<td>.46</td>
</tr>
<tr>
<td>Osteocalcin, ng/mL</td>
<td>1.1 ± 0.2</td>
<td>1.3 ± 0.3</td>
<td>.28</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0885066611402156">
<p>Abbreviations: PTH, parathyroid hormone; RCU, respiratory care unit; MICU, medical intensive care unit; SICU, surgical intensive care unit, CCU, coronary care unit; CSICU, cardiothoracic surgical intensive care unit, NICU, neurosurgical intensive care unit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Data for CTX and OCN are presented in <xref ref-type="fig" rid="fig2-0885066611402156">Figure 2</xref>
. The ibandronate group had a 34% decrease in CTX from baseline on day 6 after treatment compared to a 13% rise in CTX in the placebo group (<italic>P</italic> = .03). On day 11 after treatment, CTX levels in the ibandronate group had a 7% increase that was not significantly different from baseline (<italic>P</italic> = .21) or compared with the placebo group (<italic>P</italic> = .32). C-telopeptide levels did not significantly change in the placebo group throughout the study.</p>
<fig id="fig2-0885066611402156" position="float">
<label>Figure 2.</label>
<caption>
<p>Markers of bone metabolism in CCI after treatment. (<italic>A</italic>) C-telopeptide (CTX); (<italic>B</italic>) osteocalcin. *<italic>P</italic> = .05 compared to placebo, <sup>†</sup>
<italic>P</italic> = .01 compared to placebo.</p>
</caption>
<graphic xlink:href="10.1177_0885066611402156-fig2.tif"/>
</fig>
<p>On day 11 after treatment, OCN levels increased by 78% compared to baseline in the ibandronate group (<italic>P</italic> = .01) and by 42% in the placebo group (<italic>P</italic> = .05). There were no significant differences in OCN levels between the 2 treatment groups at all points in the study.</p>
<p>None of the 20 participants enrolled in the study experienced an adverse event, including no observed fevers, musculoskeletal pain, new-onset atrial fibrillation, decline in renal function, or hypocalcemia. In the ibandronate group, calcium levels decreased significantly but remained within the normal range (<xref ref-type="fig" rid="fig3-0885066611402156">Figure 3</xref>
). Parathyroid hormone levels did not significantly change from baseline or between groups (<xref ref-type="fig" rid="fig3-0885066611402156">Figure 3</xref>).</p>
<fig id="fig3-0885066611402156" position="float">
<label>Figure 3.</label>
<caption>
<p>Serum metabolite levels in CCI after treatment. (<italic>A</italic>) Corrected calcium; (<italic>B</italic>) PTH; (<italic>C</italic>) phosphorus; (<italic>D</italic>) creatinine. *<italic>P</italic> = .01 for ibandronate group day 6 corrected calcium level compared to baseline.</p>
</caption>
<graphic xlink:href="10.1177_0885066611402156-fig3.tif"/>
</fig>
</sec>
<sec id="section9-0885066611402156">
<title>Discussion</title>
<p>A single dose of intravenous ibandronate reduced osteoclast activity for a 6-day period compared to the placebo group. However, this antiresorptive effect was relatively short-lived, as evidenced by the return of serum CTX levels to baseline by day 11.</p>
<p>Both the response magnitude (34%) and duration (6 days) of ibandronate-induced serum CTX reduction fall considerably short of those observed in postmenopausal women treated with intravenous ibandronate for osteoporosis in the DIVA study.<sup><xref ref-type="bibr" rid="bibr14-0885066611402156">14</xref></sup> However, the responses appear consistent with high levels of cytokine-mediated osteoclastogenesis in patients with CCI in the basal state, which would essentially drive bone resorption.<sup><xref ref-type="bibr" rid="bibr3-0885066611402156">3</xref>,<xref ref-type="bibr" rid="bibr5-0885066611402156">5</xref></sup> To date, there are no histological comparisons of osteoclast numbers and activity in postmenopausal women with versus without CCI.</p>
<p>The short duration of the ibandronate effect also contrasts with our previous retrospective analysis of the use of pamidronate in patients withn CCI, in which the effects on NTX levels lasted for 18 days.<sup><xref ref-type="bibr" rid="bibr12-0885066611402156">12</xref></sup> This distinction cannot be explained by differences between the respective bisphosphonates in either their affinity to bind hydroxyapatite, which determines their longevity in bone, or in their ability to inhibit the enzyme farnesyl diphosphate synthase, which defines resorptive potency.<sup><xref ref-type="bibr" rid="bibr15-0885066611402156">15</xref><xref ref-type="bibr" rid="bibr16-0885066611402156"/><xref ref-type="bibr" rid="bibr17-0885066611402156"/><xref ref-type="bibr" rid="bibr18-0885066611402156"/><xref ref-type="bibr" rid="bibr19-0885066611402156"/>–<xref ref-type="bibr" rid="bibr20-0885066611402156">20</xref></sup> Ibandronate has both a greater affinity and resorptive potency compared with pamidronate, thus these pharmacological differences are unlikely to explain the short duration of ibandronate action. Therefore, the shorter action of ibandronate noted here may arise from the lower, “osteoporosis,” dose of ibandronate (3 mg) that was administered in the face of high resorption rates. In ibandronate dose response trials, 4 to 6 mg was often required to reduce bone resorption in similarly high-turnover states, such as hypercalcemia of malignancy and metastatic bone disease.<sup><xref ref-type="bibr" rid="bibr21-0885066611402156">21</xref></sup>
</p>
<p>Alternatively, the vast majority (87%) of ibandronate in plasma is protein bound, compared to only 54% of circulating pamidronate and 26% of circulating zoledronic acid.<sup><xref ref-type="bibr" rid="bibr13-0885066611402156">13</xref>,<xref ref-type="bibr" rid="bibr22-0885066611402156">22</xref>,<xref ref-type="bibr" rid="bibr23-0885066611402156">23</xref></sup> Patients with CCI have low levels of plasma albumin and other plasma proteins, which may negatively impact the bioactivity and effective plasma concentration of ibandronate in this population.<sup><xref ref-type="bibr" rid="bibr2-0885066611402156">2</xref></sup> These and other potential pharmacodynamic factors, such as compromised renal function, may therefore contribute to the abbreviated effect of ibandronate in patients with CCI.</p>
<p>Another notable difference in the responses observed with intravenous ibandronate in the general postmenopausal osteoporosis population and postmenopausal patients with CCI studied here is that the drug did not suppress bone formation, as evidenced by OCN measurements.</p>
<p>That OCN levels increased in both the treatment and placebo groups throughout the study suggested that osteoblast activity progressively increased with time in both groups. This is quite unlike the use of ibandronate, and other bisphosphonates, in postmenopausal women when substantial reductions in serum OCN levels are noted.<sup><xref ref-type="bibr" rid="bibr14-0885066611402156">14</xref>,<xref ref-type="bibr" rid="bibr24-0885066611402156">24</xref>,<xref ref-type="bibr" rid="bibr25-0885066611402156">25</xref></sup> The reduction in formation markers, such as OCN and procollagen type 1 N-terminal propeptide, has been attributed to the coupling of resorption and formation, so that reduced resorption is invariably followed by reduced formation, and vice versa.<sup><xref ref-type="bibr" rid="bibr26-0885066611402156">26</xref></sup> Therefore, there is an apparent uncoupling between the 2 components of bone remodeling for at least the short duration of ibandronate action in patients with CCI. Indeed, several small trials have provided evidence for decreased osteoblast function in patients with CCI in the basal state, despite increased osteoclastic resorption.<sup><xref ref-type="bibr" rid="bibr27-0885066611402156">27</xref><xref ref-type="bibr" rid="bibr28-0885066611402156"/>–<xref ref-type="bibr" rid="bibr29-0885066611402156">29</xref></sup> These reductions in bone formation could conceivably arise from prolonged immobilization and/or hypercortisolemia, both of which are known to suppress osteoblasts.<sup><xref ref-type="bibr" rid="bibr5-0885066611402156">5</xref>,<xref ref-type="bibr" rid="bibr8-0885066611402156">8</xref></sup> It might seem that bisphosphonates may correct this bone formation defect through a yet uncharacterized action on osteoblast survival. However, this is unlikely as the placebo group also showed a parallel increase in bone formation.</p>
<p>None of the 20 participants enrolled in the study experienced an adverse event, including fever, musculoskeletal pain or discomfort, new-onset atrial fibrillation, decline in renal function, or clinically significant hypocalcemia. In the ibandronate group, serum calcium levels did fall, but the corrected serum calcium remained within the normal range without symptoms and signs of hypocalcemia (<xref ref-type="fig" rid="fig3-0885066611402156">Figure 3</xref>). Impressively, however, PTH levels did not significantly change from baseline or between groups (<xref ref-type="fig" rid="fig3-0885066611402156">Figure 3</xref>). It is likely that the protection from both hypocalcemia and secondary hyperparathyroidism arose from aggressive concomitant calcium and vitamin D supplementation. The safety profile of ibandronate is indeed consistent with the low adverse event rates with this drug in large trials for the prevention and treatment of osteoporosis.<sup><xref ref-type="bibr" rid="bibr14-0885066611402156">14</xref>,<xref ref-type="bibr" rid="bibr25-0885066611402156">25</xref></sup> In these trials, up to 7% of participants experienced flu-like symptoms or myalgias and only 2% had a decline in renal function in response to intravenous ibandronate.</p>
<p>In summary, we provide proof-of-concept that an intravenous bisphosphonate, in our case, ibandronate, can be used to attenuate osteoclast activity in patients with CCI. While ibandronate has an excellent safety profile, a higher dose or more potent and/or avid bisphosphonate might be required for a prolonged and perhaps more therapeutically meaningful suppression of hyperresorption in this unique population of patients with CCI. Whether prolonged osteoclast suppression might reduce bone formation further or actually reduce the risk of fracture in this population remains to be determined.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0885066611402156">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared a potential conflict of interest as follows: MZ is on the Speaker Bureau and Advisory Boards for Roche Pharmaceuticals, Novartis Pharmaceuticals and Procter and Gamble Pharmaceuticals. None of the other authors have any potential conflicts of interest to disclose.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0885066611402156">
<label>Funding</label>
<p>The author(s) received no financial support for the research and/or authorship of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0885066611402156">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollander</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mechanick</surname>
<given-names>JI</given-names>
</name>
</person-group>. <article-title>Bisphosphonates and metabolic bone disease in the ICU</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. <year>2009</year>;<volume>12</volume>(<issue>2</issue>):<fpage>190</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr2-0885066611402156">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollander</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mechanick</surname>
<given-names>JI</given-names>
</name>
</person-group>. <article-title>Nutrition support and the chronic critical illness syndrome</article-title>. <source>Nutr Clin Pract</source>. <year>2006</year>;<volume>21</volume>(<issue>6</issue>):<fpage>587</fpage>–<lpage>604</lpage>.</citation>
</ref>
<ref id="bibr3-0885066611402156">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nierman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Mechanick</surname>
<given-names>JI</given-names>
</name>
</person-group>. <article-title>Bone hyperresorption is prevalent in chronically critically ill patients</article-title>. <source>Chest</source>. <year>1998</year>;<volume>114</volume>(<issue>4</issue>):<fpage>1122</fpage>–<lpage>1128</lpage>.</citation>
</ref>
<ref id="bibr4-0885066611402156">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Cuthbertson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Harvie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Robins</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ralston</surname>
<given-names>SH</given-names>
</name>
</person-group>. <article-title>Increased bone resorption in the critically ill: association with sepsis and increased nitric oxide production</article-title>. <source>Crit Care Med</source>. <year>2002</year>;<volume>30</volume>(<issue>4</issue>):<fpage>837</fpage>–<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr5-0885066611402156">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Berghe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Van Roosbroeck</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vanhove</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wouters</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>De Pourcq</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bouillon</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Bone turnover in prolonged critical illness: effect of vitamin D</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2003</year>;<volume>88</volume>(<issue>10</issue>):<fpage>4623</fpage>–<lpage>4632</lpage>.</citation>
</ref>
<ref id="bibr6-0885066611402156">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyce</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>TNF-alpha and pathologic bone resorption</article-title>. <source>Keio J Med</source>. <year>2005</year>;<volume>54</volume>(<issue>3</issue>):<fpage>127</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr7-0885066611402156">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Eisman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Center</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Vitamin D deficiency in critically ill patients</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>18</issue>):<fpage>1912</fpage>–<lpage>1914</lpage>.</citation>
</ref>
<ref id="bibr8-0885066611402156">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Delisser</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis</article-title>. <source>J Bone Miner Res</source>. <year>2005</year>;<volume>20</volume>(<issue>1</issue>):<fpage>117</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr9-0885066611402156">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mechanick</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Nierman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Combined calcitriol-pamidronate therapy for bone hyperresorption in spinal cord injury</article-title>. <source>J Spinal Cord Med</source>. <year>2001</year>;<volume>24</volume>(<issue>4</issue>):<fpage>235</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr10-0885066611402156">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Berghe</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Endocrine evaluation of patients with critical illness</article-title>. <source>Endocrinol Metab Clin North Am</source>. <year>2003</year>;<volume>32</volume>(<issue>2</issue>):<fpage>385</fpage>–<lpage>410</lpage>.</citation>
</ref>
<ref id="bibr11-0885066611402156">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nussbaum</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Younger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vandepol</surname>
<given-names>CJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages</article-title>. <source>Am J Med</source>. <year>1993</year>;<volume>95</volume>(<issue>3</issue>):<fpage>297</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr12-0885066611402156">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nierman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Mechanick</surname>
<given-names>JI</given-names>
</name>
</person-group>. <article-title>Biochemical response to treatment of bone hyperresorption in chronically critically ill patients</article-title>. <source>Chest</source>. <year>2000</year>;<volume>118</volume>(<issue>3</issue>):<fpage>761</fpage>–<lpage>766</lpage>.</citation>
</ref>
<ref id="bibr13-0885066611402156">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Henrich</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function</article-title>. <source>J Clin Pharmacol</source>. <year>2007</year>;<volume>47</volume>(<issue>8</issue>):<fpage>942</fpage>–<lpage>950</lpage>.</citation>
</ref>
<ref id="bibr14-0885066611402156">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delmas</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Adami</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Strugala</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study</article-title>. <source>Arthritis Rheum</source>. <year>2006</year>;<volume>54</volume>(<issue>6</issue>):<fpage>1838</fpage>–<lpage>1846</lpage>.</citation>
</ref>
<ref id="bibr15-0885066611402156">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russell</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Ebetino</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy</article-title>. <source>Osteoporos Int</source>. <year>2008</year>;<volume>19</volume>(<issue>6</issue>):<fpage>733</fpage>–<lpage>759</lpage>.</citation>
</ref>
<ref id="bibr16-0885066611402156">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunford</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Coxon</surname>
<given-names>FP</given-names>
</name>
<etal/>
</person-group>. <article-title>Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2001</year>;<volume>296</volume>(<issue>2</issue>):<fpage>235</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr17-0885066611402156">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavanagh</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dunford</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group>. <article-title>The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2006</year>;<volume>103</volume>(<issue>20</issue>):<fpage>7829</fpage>–<lpage>7834</lpage>.</citation>
</ref>
<ref id="bibr18-0885066611402156">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leu</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Luegmayr</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Rodan</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Reszka</surname>
<given-names>AA</given-names>
</name>
</person-group>. <article-title>Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy</article-title>. <source>Bone</source>. <year>2006</year>;<volume>38</volume>(<issue>5</issue>):<fpage>628</fpage>–<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr19-0885066611402156">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nancollas</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Phipps</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite</article-title>. <source>Bone</source>. <year>2006</year>;<volume>38</volume>(<issue>5</issue>):<fpage>617</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr20-0885066611402156">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rondeau</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bitsch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bourgier</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs</article-title>. <source>ChemMedChem</source>. <year>2006</year>;<volume>1</volume>(<issue>2</issue>):<fpage>267</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr21-0885066611402156">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecherstorfer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steinhauer</surname>
<given-names>EU</given-names>
</name>
<name>
<surname>Rizzoli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wetterwald</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bergstrom</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate</article-title>. <source>Support Care Cancer</source>. <year>2003</year>;<volume>11</volume>(<issue>8</issue>):<fpage>539</fpage>–<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr22-0885066611402156">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Berenson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vescio</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases</article-title>. <source>J Clin Pharmacol</source>. <year>2002</year>;<volume>42</volume>(<issue>11</issue>):<fpage>1228</fpage>–<lpage>1236</lpage>.</citation>
</ref>
<ref id="bibr23-0885066611402156">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berenson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vescio</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function</article-title>. <source>J Clin Pharmacol</source>. <year>1997</year>;<volume>37</volume>(<issue>4</issue>):<fpage>285</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr24-0885066611402156">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papapetrou</surname>
<given-names>PD</given-names>
</name>
</person-group>. <article-title>Bisphosphonate-associated adverse events</article-title>. <source>Hormones (Athens)</source>. <year>2009</year>;<volume>8</volume>(<issue>2</issue>):<fpage>96</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr25-0885066611402156">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Recker</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stakkestad</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Chesnut</surname>
<given-names>CH,</given-names>
<suffix>3rd</suffix>
</name>
<etal/>
</person-group>. <article-title>Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis</article-title>. <source>Bone</source>. <year>2004</year>;<volume>34</volume>(<issue>5</issue>):<fpage>890</fpage>–<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr26-0885066611402156">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garnero</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sornay-Rendu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Claustrat</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Delmas</surname>
<given-names>PD</given-names>
</name>
</person-group>. <article-title>Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study</article-title>. <source>J Bone Miner Res</source>. <year>2000</year>;<volume>15</volume>(<issue>8</issue>):<fpage>1526</fpage>–<lpage>1536</lpage>.</citation>
</ref>
<ref id="bibr27-0885066611402156">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Berghe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Weekers</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2002</year>;<volume>56</volume>(<issue>5</issue>):<fpage>655</fpage>–<lpage>669</lpage>.</citation>
</ref>
<ref id="bibr28-0885066611402156">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van den Berghe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Weekers</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>RC</given-names>
</name>
<etal/>
</person-group>. <article-title>Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2001</year>;<volume>86</volume>(<issue>7</issue>):<fpage>3217</fpage>–<lpage>3226</lpage>.</citation>
</ref>
<ref id="bibr29-0885066611402156">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Berghe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wouters</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Weekers</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1999</year>;<volume>84</volume>(<issue>4</issue>):<fpage>1311</fpage>–<lpage>1323</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>